KeasClinical Studies ApS: Financial statements 2021
CVR: 40794492
Source: annual report 2021, Danish Business Authority
01/01/2021 – 31/12/2021
KeasClinical Studies ApS (CVR 40794492) has filed annual accounts for 2021. In 2021, the company reported a gross profit of DKK 150,954 and a net result of DKK 112,829. Equity in the 2021 report amounted to DKK 662,655. The solvency ratio was 90.8%.
- Gross Profit
- DKK 150,954
- Profit/Loss
- DKK 112,829
- Equity
- DKK 662,655
- Total Assets
- DKK 729,549
- Employees
- 0
Official annual report
Find more companies like KeasClinical Studies ApS
Build lead lists with filters on industry, geography, size and financials, and export straight to Excel.
Try the lead list generatorEvents in 2021
KeasClinical Studies ApS has published its interim report for the period September 18, 2019 to December 31, 2020.
About KeasClinical Studies ApS
KeasClinical Studies ApS is a Danish company of the type Anpartsselskab based in Aarhus C, founded in 2019. The company is registered under the industry Andre liberale, videnskabelige og tekniske tjenesteydelser i.a.n.. The company was previously named Blitz Technology ApS. The management consists of Lone Bliksted Gitz-Johansen. The company is owned by Mette Albinus Grønbæk and Blitz Holding ApS. The company has 1 employee (2020). In 2025, the company reported a gross profit of DKK -23,492 and a net result of DKK -14,372 compared with DKK -607 the year before. Equity in the 2025 report amounted to DKK 78,298.